The Safety/Efficacy of Rifaximin With/Without Lactulose in Participants With A History of Recurrent Hepatic Encephalopathy
- Conditions
- Hepatic EncephalopathyCirrhosis
- Interventions
- Registration Number
- NCT01842581
- Lead Sponsor
- Bausch Health Americas, Inc.
- Brief Summary
The purpose of the study is to evaluate if rifaximin alone or rifaximin plus lactulose delays the onset of hepatic encephalopathy (HE) in participants with cirrhosis who have had a previous episode of HE.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 222
- Male or non-pregnant, non-lactating females greater than or equal to (≥) 18 years old.
- In remission from demonstrated overt HE (Conn score 0 or 1).
- Have had one or more episodes of overt HE associated with cirrhosis within 6 months prior to screening visit (Day -7 to -1).
- Participant has a close family member or other personal contact who is familiar with the participant's HE and can provide continuing oversight to the participant and is willing to perform as caregiver for the participant during the conduct of the trial.
- Participant has been diagnosed with human immunodeficiency virus (HIV) as determined by medical history.
- History of tuberculosis infection.
- Participant has been diagnosed with chronic respiratory insufficiency.
- Participant has been diagnosed with a current infection for which they are currently taking oral or parenteral antibiotics.
- Renal insufficiency requiring routine dialysis.
- Participant has an active spontaneous bacterial peritonitis(SBP) infection.
- Intestinal obstruction or inflammatory bowel disease.
- Participant has active malignancy within the last 5 years prior to screening visit, except basal cell carcinoma of the skin, or if female, in situ cervical carcinoma that has been surgically excised.
- Current gastrointestinal (GI) bleeding or has a history of a GI hemorrhage of sufficient severity to require hospitalization and a transfusion of ≥2 units of blood within 3 months prior to screening visit.
- Participant is anemic, as defined by a hemoglobin of less than (<) 8 grams/deciliter (g/dL).
- Scheduled to receive a liver transplant within 1 month of screening.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Rifaximin 550 mg BID Rifaximin Participants will receive rifaximin 550 milligrams (mg) tablet orally twice daily (BID) for 24 weeks. Rifaximin 550 mg BID + Lactulose Rifaximin Participants will receive rifaximin 550 mg tablet orally BID with lactulose solution for 24 weeks. Lactulose dose will be self-titrated by the participant to produce 2 to 3 soft stools per day. Rifaximin 550 mg BID + Lactulose Lactulose Participants will receive rifaximin 550 mg tablet orally BID with lactulose solution for 24 weeks. Lactulose dose will be self-titrated by the participant to produce 2 to 3 soft stools per day.
- Primary Outcome Measures
Name Time Method Number of Participants Reporting a First Breakthrough HE Episode From randomization (Day 1) up to Day 170 A breakthrough HE episode was defined as an increase of the Conn score to Grade greater than or equal to (≥) 2 (ie, 0 or 1 to ≥ 2). Conn score is widely used as a measure of mental state in HE. The scale used in Conn scoring system include: Grade 0=No personality or behavioral abnormality; Grade 1=Trivial lack of awareness, euphoria, or anxiety; shortened attention span, impairment of addition or subtraction; Grade 2=Lethargy, disorientation for time, obvious personality change, inappropriate behaviour; Grade 3=Somnolence to semi-stupor, responsive to stimuli, confused, gross disorientation, bizarre behaviour; Grade 4=Coma, unable to test mental state. The time to the first breakthrough HE episode was defined as the duration between the date of first dose of study drug and the date of first breakthrough HE episode. Number of participants reporting a first breakthrough HE episode during randomization to Month 6 is presented.
- Secondary Outcome Measures
Name Time Method Number of Participants Who Died Due to Any Reason From randomization (Day 1) up to end of study (Day 186) Number of Participants Who Were Hospitalized Due to HE Episode From randomization (Day 1) up to Day 170 An HE-related hospitalization was defined as a hospitalization directly resulting from HE, or when HE events occurred during hospitalization. The time to first HE-related hospitalization was defined as the duration between the date of first dose of study drug and the date of first HE-related hospitalization. Number of participants who were hospitalized due to HE episode during randomization to Month 6 is presented.
Trial Locations
- Locations (36)
The Center for Liver and Biliary Disease
🇺🇸Baltimore, Maryland, United States
Inland Empire Liver Foundation
🇺🇸Rialto, California, United States
Asheville Gastroenterology Associates, PA
🇺🇸Asheville, North Carolina, United States
Albert Einstien Medical Center
🇺🇸Philadelphia, Pennsylvania, United States
VCU/MCV Health Systems
🇺🇸Richmond, Virginia, United States
UCSD Clinical & Translational Research Institute
🇺🇸La Jolla, California, United States
University of Florida Hepatology
🇺🇸Gainesville, Florida, United States
University of Rochester Strong Memorial Hospital
🇺🇸Rochester, New York, United States
New York University Medical Center
🇺🇸New York, New York, United States
Carolina Medical Center
🇺🇸Charlotte, North Carolina, United States
Southern California Liver Centers
🇺🇸Coronado, California, United States
Concorde Medical Group PLLC
🇺🇸New York, New York, United States
Salix Site
🇺🇸Odessa, Texas, United States
University of Wisconsin Hospital & Clinics
🇺🇸Madison, Wisconsin, United States
Columbia University Medical Ctr. Center for Liver Disease & Transplantation
🇺🇸New York, New York, United States
Research Specialists of Texas
🇺🇸Houston, Texas, United States
Amcare Research Inc
🇺🇸Houston, Texas, United States
Alamo Medical Research
🇺🇸San Antonio, Texas, United States
Methodist Hospital
🇺🇸San Antonio, Texas, United States
University of Utah Hospital
🇺🇸Salt Lake City, Utah, United States
Integris Nazh Zuhdi Transplant Institute
🇺🇸Oklahoma City, Oklahoma, United States
Mayo Clinic
🇺🇸Rochester, Minnesota, United States
Univ. of Nebraska Medical Center
🇺🇸Omaha, Nebraska, United States
Banner Research
🇺🇸Phoenix, Arizona, United States
UCSF/Fresno - CRMC
🇺🇸Fresno, California, United States
Gastroenterology Associates
🇺🇸Macon, Georgia, United States
South Denver GI
🇺🇸Englewood, Colorado, United States
Indiana University
🇺🇸Indianapolis, Indiana, United States
Delta Research Partners, LLC
🇺🇸Monroe, Louisiana, United States
Brigham and Women's Hospital Division of Gastroenterology & Hepatology
🇺🇸Boston, Massachusetts, United States
St. Louis University
🇺🇸Saint Louis, Missouri, United States
Central Iowa Hospital Corp
🇺🇸Des Moines, Iowa, United States
University of Colorado Denver
🇺🇸Aurora, Colorado, United States
Tampa General Medical Group
🇺🇸Tampa, Florida, United States
Kansas City Research Institute
🇺🇸Kansas City, Missouri, United States
UNC School of Medicine/Division of Gastroenterology and Hepatology
🇺🇸Chapel Hill, North Carolina, United States